Tesamorelin cost and pricing: what it actually costs in 2026

Last updated 2026-07-25

How much does tesamorelin actually cost per month?

There are really two different products with two very different price tags, and confusing them is the single most common mistake people make when they start pricing this out. Brand-name Egrifta (and its newer, easier-to-mix version, Egrifta SV) is the only FDA-approved tesamorelin product. It's approved specifically for reducing excess visceral fat in HIV patients with lipodystrophy . List prices for Egrifta SV commonly land somewhere between $1,000 and $2,500+ per month depending on dose, pharmacy, and whether a manufacturer savings program applies. Without insurance or assistance, a year of brand therapy can run into the tens of thousands of dollars. That's not a typo, and it's not an exaggeration for a specialty peptide biologic; it's just what self-pay branded biologics cost in the US market. Compounded tesamorelin, made by a 503A or 503B pharmacy from bulk peptide rather than the branded finished product, is priced completely differently, usually in the low hundreds of dollars per month rather than four figures. The tradeoff is that compounded product isn't FDA-approved, doesn't go through the same batch-release testing as Egrifta, and its legality depends on tesamorelin's compounding status under federal rules, which we get into below. We cover the sourcing-side numbers in more depth in tesamorelin cost, including how vial size and reconstitution affect your real cost per dose.

Why is brand-name Egrifta so expensive?

Egrifta is expensive for the same reasons most specialty biologic peptides are expensive: a narrow approved patient population, patent-protected manufacturing, and a distribution model built around specialty pharmacies rather than a retail counter. The FDA approval for tesamorelin came out of two large multicenter phase 3 trials in HIV patients with excess abdominal fat, pooled and reported with safety extension data through 52 weeks . That's a real, well-controlled evidence base, but it's also a relatively small patient population compared to, say, a cholesterol drug, and a manufacturer recovering trial costs across a smaller prescriber base tends to charge more per unit. The drug itself is also not a small molecule. It's a 44-amino acid peptide analogue of growth hormone-releasing hormone, and peptide synthesis and purification at pharmaceutical grade is inherently more expensive than making a tablet ^[1]. None of that makes the price comfortable. It does explain why it isn't going to drop to a generic-tablet price point anytime soon, since there's currently no approved generic tesamorelin on the market.

Does insurance cover tesamorelin, and for what?

Insurance coverage for tesamorelin is tied tightly to the FDA-approved indication: HIV-associated lipodystrophy with excess visceral abdominal fat. If a patient has HIV, has documented excess visceral fat, and a physician is prescribing Egrifta for that specific purpose, insurance (including many Medicaid and Medicare Part D plans, and often manufacturer copay assistance programs) has a real chance of covering it, sometimes bringing out-of-pocket cost down substantially. Outside that population, coverage essentially disappears. If someone wants tesamorelin for general fat loss, bodybuilding-adjacent GH support, or anti-aging use, that's off-label, and insurers do not pay for off-label peptide use. You are self-pay, full stop. This is where a lot of the pricing confusion online comes from: people see a headline like 'tesamorelin costs $200/month' from someone using compounded product for an off-label reason, and someone else see 'tesamorelin costs $1,800/month' from a person on insured brand-name Egrifta for HIV lipodystrophy. Both numbers can be true. They're describing different drugs, different regulatory pathways, and different patients.

Why is compounded tesamorelin so much cheaper than Egrifta?

Compounded tesamorelin skips the costs baked into a branded, FDA-approved drug: large phase 3 trials, FDA batch review, brand marketing, and patent-protected exclusivity pricing. A compounding pharmacy sources bulk tesamorelin peptide and prepares it to an individual prescription, which is a fundamentally different manufacturing and regulatory model than an approved New Drug Application product listed in Drugs@FDA ^[2]. That cost gap is real, but so is the quality gap in oversight. Bulk drug substances used in 503A compounding are governed by 21 U.S.C. 353a ^[3] and must generally appear on FDA's 503A bulks list under 21 CFR 216.23 ^[4], or the compounder's bulk substance nomination must be under active FDA review; larger 503B outsourcing facilities compound from a separate bulks list under 21 CFR 216.24 ^[5]. Compounded product does not go through the same premarket efficacy and manufacturing review as Egrifta, and FDA has published its own list of bulk substances nominated for compounding for exactly this kind of transparency ^[6]. If you're going to consider compounded tesamorelin, buy only through a provider-reviewed pathway with a licensed, audited pharmacy, and expect to pay several hundred dollars a month rather than four figures, but understand you're accepting a different risk profile than an FDA-approved product carries.

What drives the price difference between vial sizes and doses?

Tesamorelin dosing in the approved trials used a fixed subcutaneous dose (2 mg daily was the studied regimen in the main pooled phase 3 analysis) , and population pharmacokinetic modeling in HIV-infected patients versus healthy subjects has been used to understand how dose and clearance interact . In practice, cost per month scales with total peptide delivered, which means vial size, concentration after reconstitution, and how much product is wasted in mixing all move your real monthly spend up or down. A larger multi-dose vial compounded at a pharmacy is usually cheaper per milligram than several smaller single-dose vials, but only if you're actually using the full vial before it degrades. Reconstituted peptide has a shelf life, and mixing it wrong, or storing it wrong, wastes money on top of wasting drug. We walk through the mechanics in how to reconstitute tesamorelin, and dose-timing questions in best time to take tesamorelin peptide, both of which affect how efficiently you use what you're paying for.

How does tesamorelin's cost compare with other GH-axis peptides?

Tesamorelin sits at the high end of the growth hormone secretagogue category specifically because it's the one with FDA approval and phase 3 trial data behind it, not because the peptide chemistry itself is unusually exotic. A 2026 review of injectable peptide therapy for orthopaedic and sports medicine use notes that most GH-secretagogue peptides used off-label in these settings, including tesamorelin analogues, lack the same level of approved-indication safety data that branded tesamorelin carries ^[7]. | Category | Typical monthly cost | Regulatory status |

Is compounded tesamorelin legal to buy?

It depends entirely on the bulk substance status and who's compounding it. Section 503A of the Food, Drug, and Cosmetic Act, at 21 U.S.C. 353a, permits pharmacy compounding from bulk drug substances under specific conditions, generally requiring the substance to be on FDA's 503A bulks list (21 CFR 216.23) or the subject of an active nomination FDA hasn't rejected ^[3][4]. Outsourcing facilities registered under 503B follow a parallel but separate bulks list under 21 CFR 216.24 ^[5]. FDA states plainly on its compounding guidance page that '”bulk drug substance” means an active ingredient... that is intended to furnish pharmacological activity' ^[9], and this is the language that determines whether a given peptide can legally be compounded at all, versus sold as a research chemical with no legitimate clinical pathway. That distinction matters more than price. A cheap vial from an unregulated seller with no pharmacy oversight isn't a bargain, it's an unknown. This is also why the safest read on 'is this legal' is: legal compounding happens through a licensed 503A or 503B pharmacy filling an individual prescription, tied to a provider who has evaluated you, not through a direct-to-consumer research-chemical listing.

What other costs come with tesamorelin beyond the drug itself?

The sticker price on the vial is rarely the whole bill. Add in the cost of a provider visit or telehealth consult (needed for a legitimate prescription either way), the injection supplies (syringes, alcohol swabs, sharps disposal), and, for compounded product, the bacteriostatic water or diluent for reconstitution if it isn't included. Monitoring is worth budgeting for too. Trials evaluating tesamorelin in HIV-associated lipodystrophy tracked visceral adipose tissue by imaging and followed liver enzymes, IGF-1, and glucose parameters over the study period ; a responsible real-world use pattern mirrors that, meaning periodic bloodwork rather than a start-and-forget approach. If your provider is checking IGF-1 or metabolic labs a few times a year, that's a real recurring cost that belongs in your monthly-cost math, not a surprise add-on. Injection technique costs matter too, in the sense that a wasted dose from poor reconstitution or a badly chosen injection site is money down the drain. See tesamorelin how to inject and tesamorelin injection sites for the mechanics that keep you from wasting product you already paid for.

How long do you need to use tesamorelin, and how does that change total cost?

In the main pooled phase 3 trials, tesamorelin was studied over 26 weeks in the main placebo-controlled period, with a safety extension carrying follow-up out to 52 weeks . Visceral fat reduction was the primary measured outcome, and the trial design reflects a sustained-use model, not a short course. That has a direct cost implication: this isn't a one-vial fix. If your provider is treating you along the lines of the studied protocol, you should be budgeting for months of use, and the total-cost-of-therapy conversation matters more than the per-vial price. A cheaper monthly cost sustained over a year can still add up to more than a slightly pricier option used for a shorter, better-targeted cycle. We break down realistic cycle-length planning, including what happens to visceral fat measures after stopping, in tesamorelin cycle length. If you're pricing out a full cycle rather than a single vial, that's the page to read next.

Are there cheaper alternatives that work as well?

Not with the same evidence base, no. Tesamorelin's approval rests on phase 3 data showing meaningful visceral adipose tissue reduction in HIV lipodystrophy patients , and a 2026 meta-analysis of randomized controlled trials reinforced its body composition and hepatic fat effects specifically in that population ^[10]. Cheaper, unapproved GH-secretagogue peptides marketed for similar goals generally don't have trials of that size or rigor behind them. A recent sports medicine review of approved and unapproved peptide therapies for musculoskeletal and athletic use makes the point that cost and evidence quality often move in opposite directions in this category: the cheapest options tend to be the least studied ^[11]. That doesn't mean every off-label or compounded use is unreasonable, but it does mean 'cheaper' and 'equivalent' are not the same claim, and nobody should market them as interchangeable. If cost is the binding constraint, the honest options are: pursue insurance coverage if you qualify under the approved indication, ask about manufacturer patient assistance for Egrifta, or work with a provider-reviewed compounded pathway with real pharmacy oversight, rather than chasing the lowest listed price online with no clinical relationship attached.

Where can you actually get tesamorelin, and what should you check before paying?

Two legitimate paths exist. First, a prescription for branded Egrifta SV filled through a specialty pharmacy, which is the only route with full FDA-approved manufacturing and labeling behind it, findable in the Drugs@FDA database ^[2]. Second, a compounded tesamorelin prescription filled by a licensed 503A or 503B pharmacy, following a provider evaluation. Before paying anyone for tesamorelin, check three things: is there an actual prescribing provider involved (more than a checkout page), is the pharmacy licensed and named (not anonymous), and can you get a real certificate of analysis or batch documentation for compounded product. Tesamorelin Co works from a provider-reviewed model precisely because those checks are where most of the real risk in this category sits, and it names the fulfilling pharmacy partner rather than routing you to an anonymous seller. If a price looks dramatically lower than everything else you've seen with no provider and no named pharmacy attached, that's not a deal. That's a red flag, and it's the single most common way people end up with product of unknown purity, unknown potency, or both.

Frequently asked questions

How much does tesamorelin cost per month without insurance?

Brand-name Egrifta SV without insurance commonly runs from roughly $1,000 to over $2,000 per month depending on pharmacy and dose. Compounded tesamorelin from a licensed 503A or 503B pharmacy usually costs several hundred dollars a month instead, though it lacks FDA approval and the batch testing that comes with it.

Does insurance cover tesamorelin (Egrifta)?

Insurance can cover Egrifta when it's prescribed for its FDA-approved indication, HIV-associated lipodystrophy with excess visceral abdominal fat. Coverage for off-label use (general fat loss, anti-aging, athletic use) is essentially nonexistent; insurers don't pay for uses outside the approved label.

Why is Egrifta so much more expensive than compounded tesamorelin?

Egrifta's price reflects FDA New Drug Application review, large phase 3 trial costs, patent-protected manufacturing, and specialty-pharmacy distribution. Compounded tesamorelin skips those costs by using bulk peptide compounded to prescription, which is why it's cheaper, but it also skips the same premarket efficacy and manufacturing review.

Is buying compounded tesamorelin legal?

It can be, if it comes from a licensed 503A or 503B pharmacy compounding from a bulk substance permitted under 21 U.S.C. 353a and the relevant FDA bulks list, tied to an individual prescription. Buying from an unlicensed seller with no provider involved sits outside that legal framework.

What is the FDA-approved use for tesamorelin?

Tesamorelin (Egrifta) is FDA-approved to reduce excess visceral abdominal fat in HIV patients with lipodystrophy, based on pooled phase 3 trial data with safety extension through 52 weeks. Any use outside that specific population and indication is off-label.

How long do you need to take tesamorelin to see results, and does that affect cost?

The main trials measured visceral fat reduction over a 26-week placebo-controlled period, with safety follow-up to 52 weeks. Because meaningful results were measured over months, not weeks, realistic cost planning should budget for a sustained course rather than a single short trial run.

Are there manufacturer savings programs for Egrifta?

Manufacturer patient assistance and copay programs for Egrifta exist and can meaningfully reduce out-of-pocket cost for eligible, insured patients being treated for the approved indication. Availability and terms depend on the manufacturer's current program and your insurance status, so check directly with the prescribing pharmacy or manufacturer program.

Does dose affect how much tesamorelin costs per month?

Yes. The studied phase 3 dosing regimen was a fixed subcutaneous dose, and total monthly cost scales with total peptide used, which is affected by vial size, reconstitution efficiency, and how much product is wasted in mixing. Larger vials compounded efficiently are usually cheaper per milligram if used before they degrade.

What's the cheapest legitimate way to get tesamorelin?

For the approved indication, pursuing insurance coverage plus manufacturer assistance for brand Egrifta is usually cheapest overall. Outside that indication, a provider-reviewed compounded pathway through a licensed, named pharmacy is the lowest-cost legitimate option; unverified sellers with no prescriber or named pharmacy are not a legitimate cheap option, regardless of price.

Why do online prices for tesamorelin vary so widely?

Because 'tesamorelin' online can mean an FDA-approved branded biologic, a compounded prescription product, or an unregulated research-chemical listing with no clinical oversight at all. Those are different products with different regulatory status, which is why prices can range from under $200 to over $2,000 for what looks like the same word on a page.

Does compounded tesamorelin work as well as Egrifta?

There's no head-to-head trial answering that directly. Egrifta's efficacy rests on controlled phase 3 data in HIV lipodystrophy patients; compounded product relies on the same peptide chemistry but without matching premarket testing or batch consistency review, so its real-world reliability depends heavily on the individual compounding pharmacy's quality controls.

Is tesamorelin covered under Medicare or Medicaid?

Coverage is possible under Medicare Part D or Medicaid when tesamorelin (Egrifta) is prescribed for the FDA-approved indication of HIV-associated lipodystrophy with excess visceral fat, subject to each plan's formulary and prior authorization rules. Off-label prescriptions are not a covered benefit under either program.

Sources

1. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (PMID 41490200): Cost and access for peptide therapies in orthopaedic practice track regulatory approval status closely
2. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (PMID 41476424): Most off-label GH-secretagogue peptides used in sports medicine lack the approved-indication safety data that branded tesamorelin has
3. PubMed, Tesamorelin (Nature Reviews Drug Discovery, PMID 21283099): Tesamorelin is a 44-amino acid peptide analogue of growth hormone-releasing hormone
4. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (PMID 41966639): Cost and evidence quality often move in opposite directions among GH-axis peptides, with cheaper options generally less studied
5. FDA, Drugs@FDA database: Egrifta is listed as the FDA-approved tesamorelin product with full manufacturing and labeling review, unlike compounded product
6. FDA, Bulk drug substances used in compounding under section 503A: FDA defines a bulk drug substance as an active ingredient intended to furnish pharmacological activity, the standard used to determine legal compounding status
7. eCFR, 21 CFR 216.23, the 503A Bulks List: 503A pharmacy compounding from bulk substances generally requires the substance to be on the 503A bulks list or under active FDA nomination review
8. eCFR, 21 CFR 216.24, the 503B Bulks List: 503B outsourcing facilities compound from a separate bulk drug substances list distinct from the 503A list
9. Cornell Legal Information Institute, 21 U.S.C. 353a, pharmacy compounding: Section 503A of the FDCA permits pharmacy compounding from bulk drug substances under specified conditions
10. FDA, Bulk drug substances nominated for use in compounding (current list): FDA maintains a published list of bulk substances nominated for compounding for transparency purposes
11. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin: meta-analysis of RCTs (PMID 41545261): A 2026 meta-analysis of randomized controlled trials confirms tesamorelin's body composition and hepatic fat effects in HIV-associated lipodystrophy
12. PubMed, Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects (PMID 25358450): Population pharmacokinetic modeling has characterized tesamorelin dose and clearance differences between HIV-infected patients and healthy subjects
13. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (PMID 28832410): Trials tracked visceral adipose tissue and liver enzyme changes as outcome measures during tesamorelin treatment
14. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: randomised, double-blind, multicentre trial (PMID 31611038): A randomized double-blind multicenter trial evaluated tesamorelin's effects on liver fat and metabolic parameters in HIV patients
15. PubMed, Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (PMID 22298602): Tesamorelin is FDA-approved specifically for reducing excess visceral fat in HIV patients with lipodystrophy
16. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials (PMID 20554713): The main pooled phase 3 trials studied a fixed daily subcutaneous dose over a 26-week placebo-controlled period with safety extension data to 52 weeks